Cell Cure Neurosciences

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More

Mesoblast-stock

Stem cell studies continue to make big news with a mixed bag of trends, and some good stem cell news and others not so much. Mesoblast ($MESO) had its stock suspended for quite so time recently in anticipation of a big announcement. When that news came today it was discouraging in the form of its partner …

Stem cell news bites: Mesoblast, BioTime, MS, FDA Warning, & More Read More »

Advanced Cell Technology pub: Trial for Macular Degeneration

ACT-FIgure-1-

The stem cell biotech Advanced Cell Technology (ACT) reported new, positive data in a paper in Lancet from their clinical trials using retinal pigmented epithelial cells (RPEs) made from human embryonic stem cells (hESC) for treatment of different forms of macular degeneration (MD). The paper was entitled “Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related …

Advanced Cell Technology pub: Trial for Macular Degeneration Read More »

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy

Cell-Cure-Logo

Stem cell biotech BioTime announced the news today that its subsidiary Cell Cure Neurosciences (Cell Cure) has filed an IND with the FDA for an embryonic stem (ES) cell-based therapy for Dry age-related macular degeneration (AMD). The product to be tested is OpRegen, which the company indicates is “the first IND for an ES cell-based …

BioTime’s Cell Cure Files IND with FDA for ES cell AMD therapy Read More »